ArticleBreast cancer (Dove Medical Press)2026
Inhibition of MCCC2 Impedes TNBC Progression by Downregulating Leucine Metabolism-Dependent mTOR Signaling.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methylcrotonoyl-CoA carboxylase 2 (MCCC2) has been linked to the progression of multiple tumors, whereas the mTOR has a well-documented role in TNBC. However, the contribution of MCCC2 to TNBC progression and its potential regulation of mTOR signaling remains unclear. This study seeks to assess the functional effect of MCCC2 silencing and tumorigenesis of TNBC, and to investigate whether these effects are mediated through modulation of the mTOR signaling pathway in a leucine-dependent manner. Methods: The GEPIA database was utilized to assess MCCC2 expression and its prognostic significance in breast cancer. Functional assays were employed to evaluate the biological effects of MCCC2 knockdown. The CPTAC database was used to explore MCCC2-associated signaling pathways. The involvement of the mTOR pathway was further examined by combining MCCC2 knockdown with rapamycin treatment and leucine-deprivation experiments. Results: MCCC2 expression was significantly elevated in breast cancer tissues and associated with poor prognosis. Knockdown of MCCC2 in TNBC cells inhibited proliferation, migration, invasion, and tumor growth. Bioinformatic analyses revealed a strong association between MCCC2 and several oncogenic pathways, including mTOR, MYC/MYCN, NRF2, and RTK. Notably, the inhibitory effects of MCCC2 knockdown were reversed by rapamycin and abolished under leucine-free culture conditions, suggesting a leucine-dependent mechanism of mTOR regulation. Conclusion: MCCC2 promotes TNBC progression by activating the mTOR signaling pathway in a leucine-dependent manner. Targeting MCCC2 and its metabolic axis may represent a promising therapeutic strategy for TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.